(1-氰基-2-氧代丙基)钠 | 70807-22-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (1-氰基-2-氧代丙基)钠
• 中文别名: 氰基丙酮钠盐
• 英文名称: sodium 1-cyanoprop-1-en-2-olate
• 英文别名: cyanoacetone sodium salt；(1-cyano-2-oxopropyl)sodium；sodium;3-oxobutanenitrile
• CAS: 70807-22-6
• 化学式: C₄H₄NO*Na
• mdl: MFCD00236391
• 分子量: 105.072
• InChiKey: YYIONPHFSWONBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.06
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1-氰基-2-氧代丙基)钠 、 2-氯乙酰乙酸乙酯 以 水 为溶剂， 反应 1.5h， 以77%的产率得到ethyl 4-acetyl-5-amino-2-methylfuran-3-carboxylate
  参考文献：
  名称：

  N-Heterocyclic Carbene-Catalyzed Annulation of α-Cyano-1,4-diketones with Ynals

  摘要：

  In this paper, the first stereoselective annulation reaction between alpha-cyano-1,4-diketones and ynals, mediated by catalytic amounts of a triazolium salt precatalyst and cocatalytic amounts of a weak carboxylate base, is disclosed. The title transformation proceeds smoothly under mild reaction conditions and generates three contiguous stereogenic centers, one of which is a quaternary acetal carbon. This reaction tolerates a wide variety of electronically distinct substituents on both reaction partners and affords privileged bicyclic scaffolds in 61-90% isolated yields and with up to 20:1 diastereomeric preference.

  DOI：

  10.1021/ol3022287
• 作为产物：
  描述：

  5-甲基异恶唑 在 sodium methylate 作用下， 以 二氯甲烷 为溶剂， 以99%的产率得到(1-氰基-2-氧代丙基)钠
  参考文献：
  名称：

  非常规玫瑰气味：2,2-双（异戊烯基）-3-氧代丁腈及其衍生物的偶然发现和独特的嗅觉特性

  摘要：

  发布时间为致力于斯科特E.丹麦在他65之际特殊部分的部分次生日 抽象的 2,2-双（3-甲基丁-2-烯基）-3-氧代丁腈[2,2-双（异戊烯基）-3-氧代丁腈]，一种不寻常的双功能丁腈香精，具有果味的玫瑰色，绿色气味，令人惊讶检测阈值的差异（高渗空气的浓度为0.25 ng / L空气；低渗空气的浓度为19 ng / L空气）和嗅觉特征。为了研究这种显着现象，通过3-氧代-2-苯基丁腈的单烷基化或1-氰基-钠的二烷基化合成了2,2-双（3-甲基丁-2-烯基）-3-氧代丁腈的13种衍生物。 2-氧丙烷-1-化物或氰基乙酸甲酯或乙酯，或通过2，2-双（3-甲基丁-2-烯基）-3-氧代丁腈经其三氟甲磺酸乙烯酯和Negishi交叉偶联直接衍生而来。取代模式的这些系统排列使我们对潜在的结构-气味关系和简单的嗅觉发光体模型的构建有了一定的了解，尽管无法得出关于腈或羰基功能是否是该化合物的主要渗透体的最终

  DOI：

  10.1055/s-0037-1610199

文献信息

• SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF
  申请人：Figueroa Perez Santiago

  公开号：US20100305052A1

  公开（公告）日：2010-12-02

  The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridines, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

  本申请涉及新型取代的4-芳基-1,4-二氢-1,6-萘啶类化合物，其制备方法，它们用于治疗和/或预防疾病的用途，以及它们用于制造用于治疗和/或预防疾病的药物，特别是心血管疾病。
• Lewis Acid-Catalyzed Synthesis of 4-Aminopyrimidines: A Scalable Industrial Process
  作者：Ulla Létinois、Jan Schütz、Ralph Härter、Rinke Stoll、Florian Huffschmidt、Werner Bonrath、Reinhard Karge

  DOI：10.1021/op300190s

  日期：2013.3.15

  Pyrimidine synthesis starting from acrylonitrile has been known since the 1960s. The new Lewis acid-catalyzed condensation reaction allows the synthesis of 4-aminopyrimidines starting from the easily accessible chemical acrylonitrile without the need for carcinogenic chemicals and costly derivatization in up to 90% yield. The method is versatile and applicable for industrial-scale synthesis of biologically

  自1960年代以来，就已知从丙烯腈开始合成嘧啶。新的路易斯酸催化的缩合反应可从易于获得的化学丙烯腈开始合成4-氨基嘧啶，而无需致癌化学物质，且衍生化成本高达90％。该方法用途广泛，可用于工业规模的生物相关物质的合成，例如维生素B1和甲氧苄啶。
• 5-ARYL-SUBSTITUTED DIHYDROPYRIDOPYRIMIDINES AND DIHYDROPYRIDAZINES AND USE THEREOF AS MINERAL CORTICOID ANTAGONISTS
  申请人：Figueroa Perez Santiago

  公开号：US20100035902A1

  公开（公告）日：2010-02-11

  The present application relates to novel aryl-substituted heterobicyclic compounds, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

  本申请涉及新颖的芳基取代杂双环化合物，其制备方法，它们用于治疗和/或预防疾病的用途，以及它们用于制造治疗和/或预防疾病的药物，特别是心血管疾病。
• TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD
  申请人：Von Nussbaum Franz

  公开号：US20120004203A1

  公开（公告）日：2012-01-05

  The present invention relates to novel heterocyclically fused diaryldihydropyrimidine derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of disorders of the lung and the cardiovascular system.

  本发明涉及新颖的杂环融合二芳基二氢嘧啶衍生物，涉及它们的制备方法，涉及它们单独或与其他物质结合用于治疗和/或预防疾病，以及涉及它们用于制备用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防肺部和心血管系统疾病的药物。
• [EN] PYRAZOLOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS PYRAZOLOPYRIMIDINES EN TANT QU'INHIBITEURS DE PI3 KINASE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013028263A1

  公开（公告）日：2013-02-28

  The present invention relates to compounds of formula (I) in which R1, R2, R3 and n have the meaning given in the specification and also relates to the use of these pyrazolopyrimidine derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3'OΗ kinase family (hereinafter PI3 kinases), wherein the compounds of formula (I) are described as selective inhibitors of PI3K[beta] activity.

  本发明涉及式(I)中R1、R2、R3和n的化合物，其中R1、R2、R3和n的含义如规范中所述，并且还涉及使用这些吡唑吡嘧啶衍生物来调节磷脂酰肌醇3'羟基激酶家族（以下简称PI3激酶）的活性或功能，其中式(I)的化合物被描述为PI3K[beta]活性的选择性抑制剂。